Related Experiment Video
Updated: Mar 17, 2026
A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy
Published on: September 13, 2022
Severe Elevation of Liver Tests in Choledocholithiasis: An Uncommon Occurrence With Important Clinical Implications
Saroja Bangaru1, Dwain Thiele, Jayaprakash Sreenarasimhaiah
1*Department of Internal Medicine †Division of Digestive and Liver Diseases, University Texas Southwestern Medical Center, Dallas, TX.
Insights
Dramatic elevations in liver tests are uncommon in choledocholithiasis but do not necessitate further workup if values decrease. This study found that high aminotransferase or bilirubin levels in bile duct stones often resolve without additional investigation.
Area of Science:
- Hepatology
- Gastroenterology
- Diagnostic Medicine
Background:
- Choledocholithiasis (bile duct stones) is typically not associated with significant elevations in liver enzymes or bilirubin.
- Dramatic elevations in liver tests may prompt extensive investigation for alternative diagnoses.
Purpose of the Study:
- To determine the prevalence of dramatic elevations in liver tests (AST/ALT >1000 IU/L, total bilirubin >10 mg/dL) in patients with choledocholithiasis.
- To compare clinical characteristics of patients with elevated aminotransferases versus elevated bilirubin.
- To assess the need for further workup in such cases.
Main Methods:
- Retrospective chart review of 740 patients diagnosed with choledocholithiasis via ERCP over 7 years.
- Analysis of liver function tests (LFTs) including AST, ALT, and total bilirubin.
- Comparison of clinical features between patients with elevated aminotransferases and those with elevated bilirubin.
Main Results:
- Elevated AST/ALT (>1000 IU/L) occurred in 6.1% of patients; elevated total bilirubin (>10 mg/dL) in 4.7%.
- Both elevated aminotransferases and bilirubin levels decreased significantly by discharge.
- Patients with elevated aminotransferases were more likely to be female, have had prior cholecystectomy, and have a smaller common bile duct diameter.
Conclusions:
- Dramatic elevations in AST/ALT or bilirubin in patients with known choledocholithiasis do not require extensive workup for other etiologies.
- Monitoring for significant decrease in LFTs is sufficient; normalization within the same hospitalization is not always necessary.
Background And Aims:
Choledocholithiasis is not commonly associated with dramatic elevations in aminotransferase or total serum bilirubin. Ours is the largest case series thus far studying the prevalence of dramatic elevations in liver tests associated with choledocholithiasis.
Materials And Methods:
We performed a retrospective chart review of all patients with choledocholithiasis diagnosed on endoscopic retrograde pancreatocholangiogram at a tertiary referral hospital over 7 years. We identified 740 patients with available liver tests and determined the prevalence of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >1000 IU/L and of total serum bilirubin >10 mg/dL. We compared clinical characteristics of these 2 nonoverlapping groups.
Results:
Of 740 patients, AST and/or ALT values >1000 IU/L were present in 45 (6.1%) patients. On average AST and ALT decreased 79% and 56%, respectively, at discharge 1 to 8 days later. Total serum bilirubin levels >10 mg/dL were present in 35 (4.7%) patients and decreased by an average of 64% at discharge 1 to 8 days later. When compared with the group with total serum bilirubin >10 mg/dL, the group with elevated aminotransferases had significantly more females (93% vs. 43%, P<0.001), had smaller common bile duct diameter (8.5 vs. 10.6 mm, P=0.04), and were more likely to have had a prior cholecystectomy (40% vs. 14%, P=0.01). These 80 patients had higher utilization of health resources: half had additional laboratory studies and one fourth had additional imaging studies performed.
Conclusions:
In patients with high AST and/or ALT and serum total bilirubin levels with known choledocholithiasis, elaborate work up to look for another etiology is not required. As long as the values decrease significantly, they do not need to be followed until they normalize in the same hospitalization.
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:26Endoscopic Procedures V: ERCP
Patient...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...